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Elucidating the underlying pathogenic pathways in Parkinson’s disease will be critical for targeted drug
development. In this issue of Neuron, Dhungel et al. (2015) utilize a yeast model to establish a link between
VPS35 and EIF4G1 in a-synuclein-related neurodegeneration.Parkinson’s disease (PD) is the most
common age-related neurodegenerative
movement disorder. It is defined by the
asymmetric onset of motor symptoms,
including bradykinesia, rigidity, resting
tremor, and postural instability (Lees
et al., 2009). Given the prominence of mo-
tor symptoms, PD is typically considered
a movement disorder, though a number
of nonmotor features (including sleep,
gastrointestinal, and cognitive distur-
bances) are also common and often pre-
date the motor dysfunction (Lees et al.,
2009). In addition, a positive response to
dopamine replacement therapy supports
a clinical diagnosis of probable PD. A
definitive determination of PD requires
the presence of a-synuclein-positive
Lewy-related pathology (Dickson, 2012).
Although predominantly a sporadic disor-
der in nature, significant disease insights
have been gleaned from gene discovery
studies on rare multi-incident families.
Todate,mutations in six keygeneshave
been shown to cause what we consider
familial forms of PD (SNCA, LRRK2, and
VPS35 in dominantly inherited patterns
and PARKIN, PINK1, and DJ1 in reces-
sively inherited patterns) (Trinh and Farrer,
2013). These genes cause disease in mul-
tiple unrelated families, and pathogenicity
for specific mutations is well established.
A number of other genes have been impli-
cated in single or small families with in-
herited PD (e.g., EIF4G1 and DNAJC13)
or other forms of parkinsonism (e.g.,
ATP13A2 and PLA2G6) (Trinh and Farrer,
2013). Furthermore, large population-
based genome-wide association studies
have nominated 24 independent genomic
loci that influence the individual suscepti-
bility to PD, including both SNCA and
LRRK2 (Nalls et al., 2014). However,despite the numerous genetic insights
into disease etiology, current understand-
ing of the basic mechanisms and path-
ways that contribute to the pathogenesis
of PD remains limited.
In this issue of Neuron, Dhungel et al.
(2015) employ a yeast-based model sys-
tem to provide functional insight into the
human PD-related genes VPS35 and
EIF4G1, which are known to function in
regulating vacuolar transport (VPS35)
and transcription/translation mechanisms
(EIF4G1). For both genes, the mutations
identified in the original families are
missense, resulting in amino acid substi-
tutions (VPS35 p.D620N and EIF4G1
p.R1205H) that could result in gain, loss,
or toxic gain of function mechanisms.
Therefore, in order to determine the
consequence of these mutations, a
greater understanding of the normal func-
tions andmolecular pathways that involve
VPS35 and EIF4G1 is imperative. One
way to gain insight into a gene’s function
is to identify interacting genes. The au-
thors begin by performing two indepen-
dent genome-wide screens in yeast for
genes that interact with the yeast homo-
logs of EIF4G1 (called TIF4631) and
VPS35. Surprisingly, while the investiga-
tors identify a key list of genes with syn-
thetic lethal effects from these two inde-
pendent analyses, a handful of genes
that were synthetic lethal with both yeast
Vps35 and Tif4631 (EIF4G1) deletions
were also discovered. Given the known
functions of VPS35 and EIF4G1, synthetic
lethal genes involved in vacuolar trans-
port (VPS35) and transcription/translation
mechanisms (EIF4G1) were predicted,
while overlapping pathways unexpect-
edly included protein targeting and endo-
somal transport.NeuronDespite uncovering common pathways
that include both VPS35 and EIF4G1,
simultaneous deletion of VPS35 and
EIF4G1 did not cause synthetic lethality,
prompting the authors to evaluate alter-
nate modes of genetic interactions.
Intriguingly, overexpression of EIF4G1 (or
yeast homolog tif4631) in yeast lacking
VPS35 was highly toxic, while restoring
wild-type, but not mutant (p.D620N),
VPS35could rescue this phenotype.Given
that VPS35 is a known component of the
retromer complex (which regulates recy-
cling, sorting, and trafficking between the
endosomal and Golgi network), the au-
thors predicted that EIF4G1 toxicity under
conditions of VPS35 deficiency may be
due to loss of retromer function. In support
of this hypothesis, deficiency of other ret-
romer components (e.g., VPS26) similarly
enhanced EIF4G1-related toxicity. The
authors then showed that the toxicity was
due to proteotoxic stress, as concomitant
EIF4G1 overexpression and VPS35 defi-
ciency resulted in focal accumulation
of Hsp104-GFP (a reporter of protein
misfolding/aggregation), as well as an
increase in endoplasmic reticulum (ER)
stress and activation of the unfolded pro-
tein response (UPR). These findings sug-
gest that a functional retromer complex
plays an essential role in combatting and
ameliorating the abnormal accumulation
and misfolding of proteins instigated by
an upregulation in EIF4G1 expression.
In addition, overexpression of the yeast
sortilin homolog Vps10 (a transmembrane
protein that regulates neuronal viability
and neurotrophic signaling) was also pro-
tective in the EIF4G1 upregulation-VPS35
deletion system, which could indicate
that VPS35 alleviates EIF4G1 toxicity
throughVPS10. Asmembers of the human85, January 7, 2015 ª2015 Elsevier Inc. 1
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SorCS1/2/3) have also been implicated
in neurodegeneration, these observations
may pinpoint a general process by which
protein accumulation/aggregation disor-
ders could be targeted therapeutically.
Given the central role of a-synuclein
in PD pathophysiology, building connec-
tions between the other PD-associated
genes should eventually lead back to the
universal pathognomonic Lewy-related
pathology. Gitler and colleagues had
previously used a similar approach to
investigate toxicity related to a-synuclein
overexpression in yeast (Gitler et al.,
2009; Yeger-Lotem et al., 2009). In the
present study, the authors show that
loss of EIF4G1 does not impact a-synu-
clein toxicity, yet EIF4G1 overexpression
(toxic in the VPS35 deletion model) sup-
pressed a-synuclein-related toxicity in
their earlier work. Conversely, Dhungel
et al. (2015) demonstrated that VPS35
deletion enhanced a-synuclein-related
toxicity and increased inclusion forma-
tion. In an established transgenic a-synu-
clein murine model, either knockdown or
expression of mutant VPS35 increased
neuronal loss, while overexpression of
wild-type VPS35 was neuroprotective
and lowered the accumulation of a-synu-
clein. Overexpression of wild-type VPS35
also appeared to lower or block the up-
take of extracellular recombinant a-synu-
clein fibrils in a seeding model. The hy-
pothesis that a-synuclein pathology can
propagate or spread to neighboring cells
in PD has recently gained considerable
interest (Guo and Lee, 2014), and the
current study may implicate a role for the
retromer complex in this process.
The results of this study provide the
field with important mechanistic insights
into the possible pathogenic processes
associated with PD due to mutations in
VPS35 or EIF4G1. Dysfunction of the
noted pathways of protein translation,
transport, and recycling/clearance is
believed to be fundamental in protein
aggregation disorders in general. Defi-
ciency of the retromer complex has also
been implicated in Alzheimer’s disease,
so why this specific VPS35 mutant
(p.D620N) results in a typical PD pheno-
type remains to be resolved. In addition,
the results highlight a list of genes that
exacerbate toxicity under conditions of
either VPS35 or EIF4G1 loss of function,2 Neuron 85, January 7, 2015 ª2015 Elsevierproviding additional insight into individual
and shared pathways linked to these
two PD-associated genes. In future
studies, it will be interesting to determine
whether the pathways linked to VPS35
and EIF4G1 are also associated with
other PD genes. As the most frequent
and clinically relevant genetic mutations
and risk factors in PD are in the LRRK2
gene (Ross et al., 2011), the fact that
either VPS35 or VPS26 overexpression
can rescue locomotor and lifespan defi-
cits in a mutant LRRK2 Drosophila model
(Linhart et al., 2014) may implicate the
involvement of a common pathogenic
pathway(s) in PD.
The complexity and systemic nature of
PD means it is likely that dysfunction can
occur directly at the specific protein level
or at a higher level of cellular processes.
The current lack of progress in developing
therapeutics to either slow/halt the pro-
gression or even prevent clinical onset
has been disappointing, though the mere
identification of the primary gene targets
may not be sufficient to accomplish this
endeavor. In the future, it will likely be
critical to characterize the dysfunctional
pathway(s), which may also identify
upstream or downstream targets that
could be more amenable to intervention,
as well as provide insight to facilitate
biomarker development.
Considering that the original pathogenic
substitution (p.R1205H) is being detected
in an increasing number of apparently
healthy subjects, the pathogenicity of
EIF4G1mutations inPD is still under inves-
tigation. The work of Dhungel et al. (2015)
provides an innovative new approach to
identify potential genetic factors, as well
as disease-modifying candidates in PD.
Importantly, the authors do show similar
effects across different model systems,
from yeast to worm to mouse. A similar
approach identified ataxin 2 as a strong
modifier of TDP-43 toxicity in yeast, and
the gene was subsequently established
as a major risk factor for ALS in humans
(Elden et al., 2010). Given the lack of large
families available with Mendelian forms
of PD without a known genetic cause,
it is becoming increasingly important to
generate novel approaches to identify
candidate genes for PD.
Next-generation sequencing methods
have now revolutionized the way we view
gene discovery studies. Identification ofInc.the pathogenic VPS35 mutation via
exome sequencing on multi-incident fam-
ilieswas the first example of this approach
in PD (Vilarin˜o-Gu¨ell et al., 2011; Zimprich
etal., 2011).Despite thisearlysuccess, the
advances in next-generation sequencing
technology have not led to the avalanche
of PD-linked genes as hoped, with only a
small number of additional rare variants
being identified and proposed to be path-
ogenic (e.g., DNAJC13) (Vilarin˜o-Gu¨ell
et al., 2014). However, as next-generation
sequencing becomes more common-
place in genetics, we will likely witness
an exponential growth in the abundance
of rare or unique genetic variants of un-
known clinical significance. Gene burden
testing (i.e., the total number of rare muta-
tions in a series of patients compared to
controls) is a population-based genetic
approach to confirm the role of candidate
genes in disease. Although gene burden
tests may pinpoint a few key genes that
harbor rare disease-relevant variants,
determining pathogenicity of the individ-
ual variants may not be possible from a
genetics perspective. It will be crucial to
develop functional readouts into which
each rare/unique variant can be placed
and functional pathogenicity determined.
Thus, the results of the present study
provide a good example of how this
could work; the demonstration that either
VPS35 knockdown ormutant VPS35 influ-
ences a-synuclein accumulation or fibril
uptake provides a platform for the testing
of other rare VPS35 mutants detected in
patients.
In summary, the present work of Dhun-
gel et al. (2015) provides a foundation for
future genetic and functional studies
involving EIF4G1, VPS35, and a-synuclein
in PD. Further genetic studies may help to
determine whether EIF4G1 mutations are
pathogenic and clarify the disease mech-
anisms associated with specific muta-
tions. However, it is likely that unbiased
screens, such as those presented herein,
and hypothesis-driven functional studies
will be necessary to resolve the pathways
involved and drive the generation of novel
strategies for therapeutic intervention.
REFERENCES
Dhungel, N., Eleutri, S., Li, L., Kramer, N., Chartron,
J., Spencer, B., Kosberg, K., Fields, J., Klodjan, S.,
Adame, A., et al. (2015). Neuron 85, this issue,
76–87.
Neuron
PreviewsDickson, D.W. (2012). Cold Spring Harb Perspect
Med 2.
Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin,
A.S., Johnson, B.S., Fang, X., Armakola, M.,
Geser, F., Greene, R., Lu, M.M., et al. (2010). Na-
ture 466, 1069–1075.
Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn,
K.E., Hamamichi, S., Hill, K.J., Caldwell, K.A.,
Caldwell, G.A., Cooper, A.A., Rochet, J.C., and
Lindquist, S. (2009). Nat. Genet. 41, 308–315.
Guo, J.L., and Lee, V.M. (2014). Nat. Med. 20,
130–138.
Lees, A.J., Hardy, J., and Revesz, T. (2009). Lancet
373, 2055–2066.
Linhart, R., Wong, S.A., Cao, J., Tran, M., Huynh,
A., Ardrey, C., Park, J.M., Hsu, C., Taha, S., Peter-
son, R., et al. (2014). Mol. Neurodegener. 9, 23.Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Her-
nandez, D.G., Saad, M., DeStefano, A.L., Kara, E.,
Bras, J., Sharma, M., et al.; International Parkin-
son’s Disease Genomics Consortium (IPDGC);
Parkinson’s Study Group (PSG) Parkinson’s
Research: The Organized GENetics Initiative
(PROGENI); 23andMe; GenePD; NeuroGenetics
Research Consortium (NGRC); Hussman Institute
of Human Genomics (HIHG); Ashkenazi Jewish
Dataset Investigator; Cohorts for Health and Aging
Research in Genetic Epidemiology (CHARGE);
North American Brain Expression Consortium
(NABEC); United Kingdom Brain Expression Con-
sortium (UKBEC); Greek Parkinson’s Disease Con-
sortium; Alzheimer Genetic Analysis Group (2014).
Nat. Genet. 46, 989–993.
Ross, O.A., Soto-Ortolaza, A.I., Heckman, M.G.,
Aasly, J.O., Abahuni, N., Annesi, G., Bacon,
J.A., Bardien, S., Bozi, M., Brice, A., et al.;
Genetic Epidemiology Of Parkinson’s Disease
(GEO-PD) Consortium (2011). Lancet Neurol.
10, 898–908.NeuronTrinh, J., and Farrer, M. (2013). Nat Rev Neurol 9,
445–454.
Vilarin˜o-Gu¨ell, C., Wider, C., Ross, O.A., Dachsel,
J.C., Kachergus, J.M., Lincoln, S.J., Soto-Orto-
laza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A.,
et al. (2011). Am. J. Hum. Genet. 89, 162–167.
Vilarin˜o-Gu¨ell, C., Rajput, A., Milnerwood, A.J.,
Shah, B., Szu-Tu, C., Trinh, J., Yu, I., Encarnacion,
M., Munsie, L.N., Tapia, L., et al. (2014). Hum. Mol.
Genet. 23, 1794–1801.
Yeger-Lotem, E., Riva, L., Su, L.J., Gitler, A.D.,
Cashikar, A.G., King, O.D., Auluck, P.K., Geddie,
M.L., Valastyan, J.S., Karger, D.R., et al. (2009).
Nat. Genet. 41, 316–323.
Zimprich, A., Benet-Page`s, A., Struhal, W., Graf,
E., Eck, S.H., Offman, M.N., Haubenberger, D.,
Spielberger, S., Schulte, E.C., Lichtner, P., et al.
(2011). Am. J. Hum. Genet. 89, 168–175.New Neurons Don’t Talk BackJacques I. Wadiche1 and Linda Overstreet-Wadiche1,*
1Department of Neurobiology, McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*Correspondence: lwadiche@uab.edu
http://dx.doi.org/10.1016/j.neuron.2014.12.047
GABAergic interneurons enforce highly sparse activity patterns in principal neurons of the dentate gyrus.
In this issue of Neuron, Temprana et al. (2015) show that immature adult-born neurons largely function inde-
pendently of inhibitory feedback circuits, neither receiving nor generating feedback inhibition.Two hallmarks of the adult dentate gyrus
that distinguish it from most other brain
regions are the highly sparse patterns of
neural activation and the continual incor-
poration of new neurons from resident
stem cells. Sparse activation refers to
the small percentage of principal dentate
granule cells (GCs) that spike during
behaviorally relevant stimuli on a back-
ground of even lower spiking activity (Ai-
mone et al., 2011; Piatti et al., 2013).
Low levels of GC spiking result primarily
from GABAergic circuits that generate
powerful feedforward and backward inhi-
bition (Ewell and Jones, 2010; Coulter
et al., 2011). Yet within the largely silent
granule cell layer, neurogenesis produces
a continually renewing small population
of putative hyperexcitable immature GCs
endowed with higher intrinsic excitability
and reduced levels of inhibition compared
with their mature neighbors (Marı´n-Burginet al., 2012; Dieni et al., 2013). Under-
standing the relationship between excit-
able immature neurons and sparse
dentate coding is a major challenge in
the fields of adult neurogenesis and den-
tate function.
Mossy fiber axons originating from den-
tate GCs exhibit two types of functional
terminals. Giant mossy fiber boutons pro-
vide powerful excitation to a few CA3
pyramidal cells and glutamatergic hilar
mossy cells, whereas highly abundant en
passant boutons innervate a large number
of GABAergic interneurons (Henze et al.,
2000). Mossy fiber recruitment of inter-
neurons that project back to the dentate
is proposed to provide a competitive
form of feedback inhibition necessary
for the formation of GC place fields and
rate coding (Renno´-Costa et al., 2010). In
the current issue of Neuron, Temprana
et al., (2015) provide new insight intothe involvement of mature and immature
GCs in dentate feedback inhibition.
The authors measure feedback inhibi-
tion by selectively expressing channelrho-
dopsin (ChR2) in three classes of GCs ac-
cording to their cellular birth date. GCs
generated in developing mice represent
the majority of mature GCs in the adult.
Adult generated GCs examined 4 weeks
after cell birth represent immature adult-
born neurons in a ‘‘critical period’’ when
they have a special role in dentate func-
tions due to their unique intrinsic and syn-
aptic properties (Aimone et al., 2011;
Sahay et al., 2011). Adult-generated
GCs examined 7–8 weeks after cell
birth represent GCs that have progressed
through the critical period and thus
presumably possess the intrinsic proper-
ties and synaptic connectivity of mature
GCs. An important technical consider-
ation is that wide-field light activation in85, January 7, 2015 ª2015 Elsevier Inc. 3
